Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2

Author: American Society of Clinical Oncology (ASCO) May 26, 2026 Duration: 19:00

Dr. Joshua Reuss returns to the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. The conversation focuses on new cancer treatment strategies for patients with advanced NSCLC and EGFR mutations, including classical EGFR alterations (exon 19 deletions, exon 21 L858R substitution) and rarer alterations (exon 20 insertion mutations). Dr. Reuss discusses results from clinical trials, including MARIPOSA and CHRYSALIS-2 and how these impacted first-line and subsequent line treatment recommendations. He looks to the future on what new evidence and potential updates are in the pipeline for this living guideline.

Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1

LINK TO FULL TRANSCRIPT


The ASCO Guidelines podcast, from the American Society of Clinical Oncology, serves as an authoritative audio companion for oncology professionals. Each episode delves into the rationale and practical application of the society's latest evidence-based clinical practice guidance. You'll hear directly from the experts who helped develop these critical recommendations, gaining a deeper understanding of the data and discussions that shape contemporary cancer care. This podcast provides a vital channel for staying current in a rapidly advancing field, translating complex guidelines into actionable knowledge for clinical practice. It’s an essential resource for anyone dedicated to implementing the highest standards in oncology, offering clarity and context that goes beyond the published document. Tune in for a focused exploration of how new research directly informs treatment pathways and patient management strategies.
Author: Language: en-us Episodes: 100

ASCO Guidelines
Podcast Episodes
Systemic Treatment of Thyroid Cancer Guideline [not-audio_url] [/not-audio_url]

Duration: 23:25
Dr. Nabil Saba shares the first evidence-based guideline on thyroid cancer from ASCO. He highlights recommendations on first- and subsequent-line systemic treatment – including multikinase inhibitors (MKIs), genomically…
Patient-Clinician Communication Guideline Update [not-audio_url] [/not-audio_url]

Duration: 31:22
Dr. Timothy Gilligan and Dr. Calvin Chou discuss the updated guideline on patient-clinician communication in oncology. They highlight clinical recommendations and strategies on topics such as communication skills and pra…
White Blood Cell Growth Factors Guideline Update [not-audio_url] [/not-audio_url]

Duration: 23:22
Dr. Bishal Gyawali and Dr. Tessa Cigler share the new, comprehensive, evidence-based update of the ASCO guideline on the use of hematopoietic colony-stimulating factors in patients with cancer. They discuss recommendatio…
Systemic Therapy in Patients With mCRPC: ASCO Living Guideline 2026.1 [not-audio_url] [/not-audio_url]

Duration: 13:37
Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients treated with ADT al…
Treatment of Multiple Myeloma: ASCO-OH (CCO) Living Guideline [not-audio_url] [/not-audio_url]

Duration: 22:18
Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic options across smold…
Management of Cancer During Pregnancy Guideline [not-audio_url] [/not-audio_url]

Duration: 34:50
Dr. Alison Loren and Dr. Ann Partridge share the latest guideline from ASCO on the management of cancer during pregnancy. They highlight the importance of this multidisciplinary, evidence-based guideline and overarching…